XOMA Royalty has the GF Score of 45, which implies that the company
might have
Worst future performance potential, or not enough data.
The GF Score is a stock performance ranking system developed by GuruFocus using five aspects of valuation, which has been found to be closely correlated to the long-term performances of stocks by backtesting from 2006 to 2021. The stocks with a higher GF Score generally generate higher returns than those with lower GF Scores. Therefore, when picking stocks, investors should invest in companies with high GF Scores. The GF Score ranges from 0 to 100, with 100 as the highest rank.
GF Score takes following five key aspects into consideration:
Each one of these components is ranked and the ranks also have positive correlation with the long term performances of stocks. The GF score is calculated using the five key aspects of analysis. Through backtesting, we know that each of these key aspects has a different impact on the stock price performance. Thus, they are weighted differently when calculating the total score. The Profitability Rank and the Growth Rank are weighted fully, while other parameters have less weight.
Based on research and backtesting result, GuruFocus believes XOMA Royalty
might have
Worst future performance potential, or not enough data.
Please click GF Score to see more details on the GF Score's 5 Key Aspects of Analysis.
XOMA Royalty (NAS:XOMA) GF Score Explanation
Based on the historical long-term performances among five valuation aspects, the GF Score is found to be closely correlated to the long-term performances of stocks. It ranges from 0 to 100, with 100 as the highest. GuruFocus divided GF Score into following 5 categories:
GF Score
Performance Potential and All-in-One Screener Examples (1)
(1) These are some simple examples. You can access our GF Score filter under All-in-One Screener’s Fundamental tab.
XOMA Royalty GF Score Related Terms
XOMA vs CLYM, CTMX, ALLO: GF Score Comparison
For the Biotechnology subindustry, XOMA Royalty's GF Score, along with its competitors' market caps and GF Score data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
XOMA Royalty GF Score vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, XOMA Royalty's GF Score distribution charts can be found below:
* The bar in red indicates where XOMA Royalty's GF Score falls into.
XOMA Royalty (XOMA) has a GF Score of 45 as of Jul. 11, 2026. GF Score is a stock performance ranking system developed by GuruFocus using five aspects of valuation. View historical data on XOMA Royalty and its competitors. This is 22% below median its historical median of 58.00. Over the past decade, XOMA Royalty's GF Score has ranged from 31.00 to 81.00.
Is XOMA Royalty's GF Score too high?
XOMA Royalty's current GF Score of 45 is 22% below median its 10-year median of 58.00. Over the past 10 years, this metric has ranged from a low of 31.00 to a high of 81.00. Overall, XOMA Royalty has a GF Score™ of 45/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does XOMA Royalty's GF Score compare to CLYM and CTMX?
XOMA Royalty's GF Score of 45 can be compared against companies in the Biotechnology industry. Historically, XOMA Royalty's own GF Score has ranged from 31.00 to 81.00 over the past decade. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good GF Score for a Biotechnology company?
A good GF Score depends on the Biotechnology industry context. However, GF Score should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high GF Score mean?
A high GF Score can signal that a stock is expensive relative to its fundamentals. GF Score is a stock performance ranking system developed by GuruFocus using five aspects of valuation. View historical data on XOMA Royalty and its competitors. XOMA Royalty's current GF Score is 45, which is 22% below median its own 10-year median of 58.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is XOMA Royalty stock overvalued right now?
Based on GuruFocus' analysis, XOMA Royalty (XOMA) is currently considered Significantly Overvalued. The stock's GF Value™ is $18.90, compared to a current price of $44.22 — trading 134% above its estimated fair value. The current GF Score is 45, which is 22% below median its 10-year median of 58.00. XOMA Royalty's overall GF Score™ is 45/100 with 9 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is GF Score calculated?
GF Score is calculated from a company's financial statements. For XOMA Royalty (XOMA), the current GF Score is 45 as of Jul. 11, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is XOMA Royalty (XOMA) Overvalued in 2026?
Based on GuruFocus' analysis, XOMA Royalty stock appears to be overvalued.
The current stock price of $44.22 is trading 134% above its estimated GF Value™ of $18.90.
GuruFocus considers XOMA Royalty to be Significantly Overvalued.
Key valuation signals for XOMA:
GF Score: 45 (22% below median its 10-year median of 58.00)
GF Value™: $18.90 vs. price of $44.22 (134% above fair value)
No single metric tells the full story. See the XOMA stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
XOMA Royalty Corp is a biotechnology royalty aggregator playing a role in helping biotech companies achieve their goal of improving human health. XOMA acquires the potential future economics associated with pre-commercial therapeutic candidates. The Company's drug royalty aggregator business is mainly focused on the acquisition of early to mid-stage clinical assets. Geographically, the company operates in Switzerland, the United States, Asia Pacific, Europe, and other regions.
45GF Score
Get the complete analysis for XOMA
GF Score is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
XOMA has been successfully added to your 